Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting

Yu, Weiyan; Wang, Yadong; Shen, Chuan; Ji, Ru; Zhang, Li; Zhao, Xin; Su, Miao; Zhang, Ying; He, Wenyan; Cao, Jianguo; Hao, Yanshuang; Chen, Shengpeng; Zhao, Caiyan.
Braz. j. infect. dis ; 21(3): 213-218, May-June 2017. tab, graf
Artigo Inglês | LILACS | ID: biblio-839216

Documentos relacionados

  1. Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting.
  2. Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs.
  3. Flares during long-term entecavir therapy in chronic hepatitis B.
  4. Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis.
  5. Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance.
  6. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
  7. ALT CHANGES AND ADVERSE EVENTS OF TELBIVUDINE IN HEPATITIS-B PATIENTS-AN EXPERIENCE OF 11 PATIENTS.
  8. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development.
  9. [Correlation between the spontaneous clearance of HBV DNA and the levels of alanine aminotransferase in chronic hepatitis B].
  10. HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.